富含半胱氨酸的血管生成诱导剂61在硬皮病中作为潜在抗纤维化和促血管生成介质
本研究探讨CYR-61在系统性硬化症(SSc)纤维化和血管生成中的作用。发现SSc患者皮肤成纤维细胞和内皮细胞中CYR61 mRNA水平降低;在SSc成纤维细胞中过表达CYR-61可减少促纤维化基因表达、增加基质降解基因和促血管生成VEGF表达,并抑制TGF-β通路;在SSc内皮细胞中过表达CYR-61增加VEGF产生,其促血管生成效应由αvβ3受体及下游AMPK、AKT和eNOS/NO通路介导。结论:CYR-61是SSc中有效的抗纤维化和促血管生成介质,促进其活性可能有益。
要点
- SSc患者皮肤成纤维细胞和内皮细胞中CYR61 mRNA水平低于健康对照。
- 过表达CYR-61可降低SSc成纤维细胞促纤维化基因并增加基质降解基因。
- CYR-61促血管生成效应由αvβ3受体及AMPK/AKT/eNOS/NO通路介导。
核心结论
- CYR-61受HDAC-5表观调控,是SSc中有效的抗纤维化和促血管生成介质,促进其活性或水平可能对SSc有益。
研究设计与样本
- 从健康者和SSc患者活检标本分离皮肤内皮细胞和成纤维细胞,通过qPCR、Western blot和ELISA检测CYR-61水平。
- 使用CYR61载体过表达或小干扰RNA敲低CYR-61,在成纤维细胞和内皮细胞中进行功能和机制研究。
主要发现
- SSc患者皮肤成纤维细胞和内皮细胞中CYR61 mRNA水平低于健康对照。
- SSc成纤维细胞中过表达CYR-61显著降低COL1A1(P=0.002)和ACTA2(P=0.04)表达,增加MMP1(P=0.002)、MMP3(P=0.004)和VEGF(P=0.03)表达。
- CYR-61的抗纤维化效应表现为延迟伤口愈合、抑制凝胶收缩、灭活TGF-β通路及与衰老相关的早期超氧化物产生。
- SSc内皮细胞中过表达CYR-61增加血管内皮细胞生长因子产生。
- CYR-61的促血管生成效应由αvβ3受体信号及下游AMPK、AKT和内皮细胞一氧化氮合酶/一氧化氮通路系统激活介导。
临床怎么用
- CYR-61可能作为SSc抗纤维化和促血管生成治疗的潜在靶点,但需进一步临床研究验证。
局限性
- 研究仅基于体外细胞实验,未涉及动物模型或临床样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We previously identified CYR61 as a histone deacetylase 5 (HDAC-5)-repressed gene in systemic sclerosis (SSc; scleroderma) endothelial cells (ECs). When overexpressed, cysteine-rich angiogenic inducer 61 (CYR-61) promoted angiogenesis in SSc ECs. This study was undertaken to examine the role of CYR-61 in fibrosis and determine the mechanisms involved in CYR-61-mediated angiogenesis in SSc. METHODS: Dermal ECs and fibroblasts were isolated from biopsy specimens from healthy subjects and patients with SSc. CYR-61 level was determined by quantitative polymerase chain reaction, Western blotting, and enzyme-linked immunosorbent assay. CYR-61 was overexpressed using a CYR61 vector or knocked down using small interfering RNA, and functional and mechanistic studies were then conducted in fibroblasts and ECs. RESULTS: Lower CYR61 messenger RNA levels were observed in dermal fibroblasts and ECs from SSc patients than in those from healthy controls. In SSc fibroblasts, overexpression of CYR-61 led to significant reduction in the expression of profibrotic genes, including COL1A1 (P = 0.002) and ACTA2 (P = 0.04), and an increase in the expression of matrix-degrading genes, including MMP1 (P = 0.002) and MMP3 (P =0.004), and proangiogenic VEGF (P = 0.03). The antifibrotic effect of CYR-61 was further demonstrated by delay in wound healing, inhibition of gel contraction, inactivation of the transforming growth factor β pathway, and early superoxide production associated with senescence in SSc fibroblasts. In SSc ECs, overexpression of CYR-61 led to increased production of vascular endothelial cell growth factor. The proangiogenic effects of CYR-61 were mediated by signaling through αvβ3 receptors and downstream activation of AMP-activated protein kinase, AKT, and the endothelial cell nitric oxide synthase/nitric oxide pathway system. CONCLUSION: CYR-61, which is epigenetically regulated by HDAC-5, is a potent antifibrotic and proangiogenic mediator in SSc. Therapeutic intervention to promote CYR-61 activity or increase CYR-61 levels might be of benefit in SSc.
引用
- Tsou PS, Khanna D, Sawalha AH, et al. Identification of Cysteine-Rich Angiogenic Inducer 61 as a Potential Antifibrotic and Proangiogenic Mediator in Scleroderma. Arthritis Rheumatol. 2019. PMID: 30884213. doi:10.1002/art.40890
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。